NCT00981617 - ALK33-005: A Study of ALKS33 (RDC-0313) in Adults With Alcohol Dependence | Biotech Hunter

Enrollment

406

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions

Alcohol Dependence

Interventions

DRUG

ALKS33 (RDC-0313) (1 mg)

1 mg ALKS33 (RDC-0313) taken once daily for 12 weeks

DRUG

ALKS33 (RDC-0313) (2.5 mg)

2.5 mg ALKS33 (RDC-0313) taken once daily for 12 weeks

DRUG

ALKS33 (RDC-0313) (10 mg)

10 mg ALKS33 (RDC-0313) taken once daily for 12 weeks

DRUG

Placebo

Matching placebo taken once daily for 12 weeks

Trial Locations (27)

10010

Alkermes Investigational Site, New York

11235

Alkermes Investigational Site, Brooklyn

19118

Alkermes Investigational Site, Philadelphia

28209

Alkermes Investigational Site, Charlotte

28562

Alkermes Investigational Site, New Bern

28601

Alkermes Investigational site, Hickory

30076

Alkermes Investigational Site, Roswell

30320

Alkermes Investigational Site, Atlanta

30328

Alkermes Investigational Site, Atlanta

32216

Alkermes Investigational Site, Jacksonville

32751

Alkermes Investigational Site, Maitland

32806

Alkermes Investigational Site, Orlando

33143

Alkermes Investigational Site, South Miami

33407

Alkermes Investigational Site, West Palm Beach

47905

Alkermes Investigational Site, Lafayette

53562

Alkermes Investigational Site, Middleton

73103

Alkermes Investigational Site, Oklahoma City

77090

Alkermes Investigational Site, Houston

84107

Alkermes Investigational Site, Salt Lake City

85712

Alkermes Investigational Site, Tucson

87102

Alkermes Investigational Site, Albuquerque

89146

Alkermes Investigational Site, Las Vegas

90660

Alkermes Investigational Site, Pico Rivera

90703

Alkermes Investigational Site, Cerritos

92056

Alkermes Investigational Site, Oceanside

92102

Alkermes Investigational Site, San Diego

02720

Alkermes Investigational Site, Fall River